Thermostable intravenous epoprostenol for the treatment of pulmonary
arterial hypertension -- a transition safety study
Abstract
Intravenous epoprostenol remains an important treatment for pulmonary
arterial hypertension (PAH) but can only be given intravenously. Until
recently the only formulation available to our patients (Flolan 10.5)
was thermolabile and required daily preparation. In 2016, we
transitioned all patients in our service to a new, thermostable
formulation (Flolan 12). All patients in our unit using epoprostenol as
of November 2016 were recruited to this prospective study which examined
for safety issues and effects on QoL, 6MWD and serum NT-proBNP. We also
collected qualitative data regarding activities of daily living. The
transition process did not result in any clinical deterioration. There
were no safety issues identified and all but one of the participants
preferred the new formulation. We therefore conclude that transitioning
patients from intravenous Flolan 10.5 to Flolan 12 is safe, does not
lead to any clinical deterioration and is acceptable to patients for
reasons of convenience.